Spectral AI announced it has secured $31.7 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) to accelerate development of its DeepView System, an artificial intelligence-driven burn wound imaging platform designed to support faster and more accurate clinical decision-making.
The funding is non-dilutive and builds on the $54.9 million already committed under the company’s existing BARDA contract, which has a total potential value of up to $150 million. Spectral AI will also contribute an additional $9.7 million toward the overall development costs associated with advancing new features of the system.
The investment will support continued development of the DeepView System as the company awaits a determination from the U.S. Food and Drug Administration regarding market authorization. The funding will also accelerate Phase II initiatives under the existing contract, including enhancements such as total body surface area mapping and analysis.
The DeepView System is being developed for use across emergency departments, trauma centers, and burn centers, both for routine burn care and as a medical countermeasure in mass casualty burn incidents. The technology is designed to provide clinicians with rapid, data-driven insights into wound healing potential, improving treatment decisions and patient outcomes.
BARDA’s support aligns with its broader mission to strengthen medical countermeasures and address gaps in the U.S. burn care infrastructure. According to the American Burn Association, approximately 1.1 million Americans experience burn injuries each year, with about 500,000 requiring emergency department care and 40,000 hospitalizations, highlighting the need for improved diagnostic tools.
Spectral AI, based in Dallas, is focused on predictive AI solutions in medical diagnostics and aims to transform wound care through its DeepView platform, which seeks to provide objective and immediate assessments of burn injuries prior to treatment.
KEY QUOTE:
“We are pleased to continue our long-standing partnership with BARDA and are grateful for its ongoing support of the DeepView System, a diagnostic tool that empowers physicians to make quick, data-driven decisions that can improve patient outcomes. Burn wound assessment is crucial in determining next-step treatment for patients, which currently largely relies on the clinical judgement of physicians. This unmet clinical need is dramatically magnified in the event of mass casualty burn incidents, or BMCIs, where the ability to triage burn patients rapidly and properly would be crucial in allocating valuable resources and managing the surgical burden. The DeepView System technology represents a new paradigm in the assessment of burn wounds and can provide meaningful clinical guidance to physicians in their diagnosis and treatment recommendations.”
Vincent Capone, Chief Executive Officer, Spectral AI
